Inflarx N.v. · NASDAQ:IFRX
Inflarx — Investor Day (November 2026)
76 slides from Inflarx's investor day presentation, Nov 3, 2026
Slide 1: Capital Markets Day
Capital Markets Day November 3, 2026
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation has been prepared by InflaRx N.V. (“InflaRx” or “we”). This presentation is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities in any jurisdiction in which such offer or solic
Slide 3: Today's agenda
Today’s agenda 01 Welcome InflaRx Participants Niels Riedemann 02 Targeting C5a/C5aR in ANCA-associated vasculitis (AAV) PROF. DR. JÖRG KÖHL Director of the Institute for Systemic Inflammation Research, University of Lübeck PROF. DR. DR. THOMAS NIELS RIEDEMANN TAAPKEN 03 The evolving treatment lands
Slide 4: Izicopan
• InflaRx N.V. Izicopan Next-generation oral C5aR inhibitor
Slide 5: Izicopan's triple threat for a potential best-in-class agent
Izicopan’s “triple threat” for a potential best-in-class agent FAST ONSET + HIGH EXPOSURE NO SAFETY SIGNALS OF CONCERN BETTER CONVENIENCE POTENTIAL FOR BETTER EFFICACY ≤1 week >100x lower pill burden to target therapeutic exposure reactive-metabolite signal 3 x drug strength per capsule (vs avacopan
Slide 6: Today's takeaways
Today’s takeaways § Izicopan has potential to expand the AAV market, with multiple differentiating features that could drive a $1.5B – $2B peak sales potential § Izicopan AAV development program is primed for generating differentiated efficacy and safety data - placebo-controlled study in patients w
Slide 7: Prof. Dr. Jörg Köhl
Prof. Dr. Jörg Köhl Targeting C5aR1-driven inflammation in ANCA vasculitis and beyond
Slide 8: ANCA-associated vasculitis
ANCA-associated vasculitis AAV A group of rare, systemic small-vessel vasculitides WHAT IT IS ANCA Necrotizing inflammation damages predominantly small blood vessels, with few or neutrophil no immune deposits. small-vessel injury Antineutrophil cytoplasmic antibodies usually target proteinase 3 ANCA
Slide 9: Pathways driving the pathogenesis of ANCA-associated vasculitis
Pathways driving the pathogenesis of ANCA-associated vasculitis • Infectious stimuli active DCs to drive Th17 à TNF/IL-1ß • TNF/IL-1ß prime neutrophils à MPO/PR3 surface transition • Complement AP activation à C5a –> neutrophil priming • ANCAs bind and activate FcgRs on neutrophils à ROS • Infection
Slide 10: Activation of complement and importance of the C5/C5a/C5aR1 axis in PMN priming
Activation of complement and importance of the C5/C5a/C5aR1 axis in PMN priming A Nakazawa et al Nat Rev Rheumatol 2019 Page 10 Prof. Dr. Jörg Köhl – Role of C5aR1 in ANCA-associated vasculitis
Slide 11: C5-deficient mice are protected from anti-MPO-induced crescent GN
C5-deficient mice are protected from anti-MPO-induced crescent GN Gou et al. Clin J Am Soc Nephrol 2013 Xiao et al. AJP 2007 Page 11 Prof. Dr. Jörg Köhl – Role of C5aR1 in ANCA-associated vasculitis
Slide 12: C5aR1-deficient mice are protected from anti-MPO-induced crescent GN
C5aR1-deficient mice are protected from anti-MPO-induced crescent GN Wildtype C5ar1-/- Wildtype C5ar1-/- Schreiber et al. JASN 2009 Brilland et al. Kidney Int Rep 2026 Page 12 Prof. Dr. Jörg Köhl – Role of C5aR1 in ANCA-associated vasculitis
Slide 13: C5aR1-deficient but not C6-deficient mice are protected
C5aR1-deficient but not C6-deficient mice are protected from anti-MPO-induced GN Xiao et al. JASN 2014 Page 13 Prof. Dr. Jörg Köhl – Role of C5aR1 in ANCA-associated vasculitis
Slide 14: Activation of FcgRs on neutrophils drives ROS release
Activation of FcgRs on neutrophils by ANCA-speficic IgG drives ROS release from neutrophils B Falk et al. Proc Natl Acad Sci 1990 Page 14 Prof. Dr. Jörg Köhl – Role of C5aR1 in ANCA-associated vasculitis
Slide 15: C5a/C5aR1 axis synergizes with FcgRs to promote inflammation
The C5a/C5aR1 axis synergizes with FcgRs to promote a pro- inflammatory environment Synergistic effects on Inflammation Page 15 Prof. Dr. Jörg Köhl – Role of C5aR1 in ANCA-associated vasculitis
Slide 16: Amplification of neutrophil activation through C5aR1 and FcgR cross-talk
Amplification of neutrophil activation through cross-talk between C5aR1 and activating FcgRs Heller et al. JI 1999 Shushakova et al. JCI 2002 Godau et al. JI 2004 Skokowa et al. JI 2005 Kumar et al. JCI 2006 Karsten and Köhl Immunobiol 2012 Schreiber et al. JASN 2009 Page 16 Prof. Dr. Jörg Köhl – Ro
Slide 17: Activation of FcgRs on neutrophils drives NET formation
Activation of FcgRs on neutrophils drives NET formation MPO AAV Serum Healthy Ctrl Serum C Kessenbrock et al. Nat Med 2009 Page 17 Prof. Dr. Jörg Köhl – Role of C5aR1 in ANCA-associated vasculitis
Slide 18: C5aR1 on neutrophils drives NETosis
C5aR1 on neutrophils drives NETosis C5aR1 drives NETosis Neutrophil C Critical driver of of inflammation in Neutrophils Silva et al J Clin Invest 2023 /Byrd et al. Sci. Immunol. 2019 Page 18 Prof. Dr. Jörg Köhl – Role of C5aR1 in ANCA-associated vasculitis
Slide 19: Cross-talk between FcgRs and C5aR1 drives NET formation
Cross-talk between FcgRs and C5aR1 on neutrophils drives NET formation Healthy Ctrl Serum C MPO AAV Serum MPO AAV Serum + Anti-C5ar1 mAb Kessenbrock et al Nat Med 2009 Huang et al. Arthr Rheumatol 2015 Page 19 Prof. Dr. Jörg Köhl – Role of C5aR1 in ANCA-associated vasculitis
Slide 20: Pathways driving the pathogenesis of ANCA-associated vasculitis
Pathways driving the pathogenesis of ANCA-associated vasculitis D Nakazawa et al Nat Rev Rheumatol 2019 Page 20 Prof. Dr. Jörg Köhl – Role of C5aR1 in ANCA-associated vasculitis
Slide 21: Autocrine C5/C5a/C5aR1 loop controls Germinal Center B cell differentiation
An autocrine C5/C5a/C5aR1 loop controls Germinal Center B cell differentiation and IgG1/IgE class switch WT C5ar1-/- Created in Einwohlt et al (unpublished) Page 21 Prof. Dr. Jörg Köhl – Role of C5aR1 in ANCA-associated vasculitis
Slide 22: Why targeting C5aR1 in ANCA-associated vasculitis?
Why targeting C5aR1 in ANCA-associated vasculitis ? Key Message 1 Key Message 2 Genetic or pharmacological C5aR1 primes and activates C5aR1 targeting strongly reduces neutrophils as the key effector disease development in cell. It is intertwined with FcgR- preclinical AAV disease models mediated neu
Slide 23: Outlook – role of C5a/C5aR1 axis in AKI to CKD transition
Outlook – role of the C5a/C5aR1 axis in the AKI to CKD transition Prof. Dr. Jörg Köhl – Role of C5aR1 in ANCA-associated vasculitis
Slide 24: C5aR1 signaling in tubular epithelial cells drives AKI-CKD transition
C5aR1 signaling in tubular epithelial cells drives AKI-CKD transition by enhancing autophagy in ischemia reperfusion injury Created in Ma. et al. Nephrol. Dial. Transplant. 2026 Page 24 Prof. Dr. Jörg Köhl – Role of C5aR1 in ANCA-associated vasculitis
Slide 25: Myeloid and pericyte C5aR1 signaling drives AKI-CKD transition
Myeloid and pericyte C5aR1 signaling drives AKI-CKD transition in a folic-acid injury model Created in Sahu et al. Am. J. Physiol. Renal Physiol. 2022 Page 25 Prof. Dr. Jörg Köhl – Role of C5aR1 in ANCA-associated vasculitis
Slide 26: References
1. Schreiber, A. et al. J. Am. Soc. Nephrol. 2009. 2. Ma, J. et al. Nephrol. Dial. Transplant. 2026. 3. Sahu, R. K. et al. Am. J. Physiol. Renal Physiol. 2022. 4. Yu, S. M.-W. et al. Am. J. Pathol. 2025. 5. McGraw, M. et al. Physiol. 2026. Created in 6. Brilland, B. et al. J. Am. Soc. 2026. 7. Brill
Slide 27: Thank you for your attention
Thank you for your attention Prof. Dr. Jörg Köhl – Role of C5aR1 in ANCA-associated vasculitis https://isef-luebeck.de/ Page 27 Prof. Dr. Jörg Köhl – Role of C5aR1 in ANCA-associated vasculitis
Slide 28: Appendix
Appendix
Slide 29: Prof. Dr. Jörg Köhl – Role of C5aR1 in ANCA-associated vasculitis
Page 29 Prof. Dr. Jörg Köhl – Role of C5aR1 in ANCA-associated vasculitis
Slide 30: Peter Merkel, MD, MPH
Peter Merkel, MD, MPH Chief, Division of Rheumatology; Professor of Medicine (Rheumatology); Professor of Epidemiology in Biostatistics and Epidemiology; University of Pennsylvania
Slide 31: Standard of Care and Unmet Medical Needs in ANCA-Associated Vasculitis
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Standard of Care and Unmet Medical Needs in ANCA-Associated Vasculitis November 3, 2026 Peter A. Merkel, M.D., M.P.H. Chief, Division of Rheumatology PI, Vasculitis Clinical Research Consortium Director, Penn Vasculiti
Slide 32: Presentation Outline
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Presentation Outline Brief introduction to the clinical spectrum of ANCA-associated vasculitis (AAV), specifically, granulomatosis with polyangiitis (GPA) / microscopic polyangiitis (MPA) Outline unmet needs for th
Slide 33: Vasculitis classification
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Variable Vessel Vasculitis Behçet's Disease Cogan’s Syndrome Single-Organ Vasculitis CNS Vasculitis Other Organs Drug-Induced Vasculitis Relapsing Polychondritis IgG4-Related Disease Vasculitis in CTD SLE, SSc, SjS, RA
Slide 34: Clinical Features of ANCA-Associated Vasculitis: GPA/MPA
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Clinical Features of ANCA-Associated Vasculitis: GPA/MPA Upper airway disease Eye disease - Nasal septum - Scleritis/episcleritis - Sinuses - Pseudotumor - Subglottic stenosis Skin/Mucosa - Mastoiditis/OM/ - Oral ul
Slide 35: Treatment of AAV: Unmet Needs
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Treatment of AAV: Unmet Needs Less toxic regimens - Glucocorticoid-sparing - CYC-sparing/avoiding - Non-sterilizing & non-teratogenic drugs - Reduction in infections More rapid induction of remission Prevention of r
Slide 36: Treatment of AAV: Unmet Needs
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Treatment of AAV: Unmet Needs Less toxic regimens - Glucocorticoid-sparing - CYC-sparing/avoiding - Non-sterilizing & non-teratogenic drugs - Reduction in infections More rapid induction of remission Prevention of r
Slide 37: Glucocorticoid Toxicity
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Glucocorticoid Toxicity Psychosis Myopathy Insomnia Hypertension Anxiety/depression Heart failure Hyperactivity Edema Cataracts Skin fragility/ecchymoses Glaucoma Osteoporosis Weight gain Os
Slide 38: Treatment of AAV: Unmet Needs
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Treatment of AAV: Unmet Needs Less toxic regimens - Glucocorticoid-sparing - CYC-sparing/avoiding - Non-sterilizing & non-teratogenic drugs - Reduction in infections More rapid induction of remission Prevention of r
Slide 39: Renal (Kidney) Disease in AAV
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Renal (Kidney) Disease in AAV Major source of morbidity and mortality in AAV Residual kidney function after initial disease or a relapse is highly predictive of mortality Rates of end-stage kidney disease (ESKD,
Slide 40: Standard of Care Treatment for AAV
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Standard of Care Treatment for AAV Based on data from >25 years of high-quality, large, multi-center, randomized, controlled, clinical trails
Slide 41: International Guidelines for Treatment of AAV
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH International Guidelines for Treatment of AAV
Slide 42: Treatment of ANCA-Associated Vasculitis
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH TREATMENT OF ANCA-ASSOCIATED VASCULITIS Remission Induction Remission Maintenance (3-6 Months) (6-48 Months-Indefinite) ??? Disease Severe Glucocorticoids Non- Methotrexate Methotrexate Rituximab Rituximab Azathioprine
Slide 43: Rituximab is the current mainstay of treatment for AAV
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Rituximab is the current mainstay of treatment for AAV Rituximab was a major advance in the treatment of AAV Repeated use (every 6 months) with continuous B cell depletion is now the usual treatment for AAV - Once
Slide 44: Standard of Care and Unmet Needs in AAV
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH
Slide 45: Post-ADVOCATE NEJM Retraction Actions
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Post-ADVOCATE NEJM Retraction Actions Amgen sponsored an independent full readjudication of the primary outcome data for all study patients and re-analyzed the results using the original statistical analysis plan A
Slide 46: ADVOCATE Report with Readjudicated Data
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH ADVOCATE Report with Readjudicated Data Note: This paper has not been peer-reviewed
Slide 47: ADVOCATE Report with Readjudicated Data: 26 Weeks
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH ADVOCATE Report with Readjudicated Data: 26 Weeks
Slide 48: ADVOCATE Report with Readjudicated Data: 52 Weeks
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH ADVOCATE Report with Readjudicated Data: 52 Weeks
Slide 49: ADVOCATE with Readjudicated Data Secondary Outcomes
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH ADVOCATE with Readjudicated Data Secondary Outcomes • None of the key secondary outcomes were impacted by the issue of adjudication or readjudication – The raw data was unaffected by the issue of readjudication, includ
Slide 50: Detailed kidney outcomes in ADVOCATE
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Detailed kidney outcomes in ADVOCATE These analyses are not impacted by the readjudication issues in ADVOCATE
Slide 51: Kidney outcomes in ADVOCATE patients with kidney disease at baseline
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Report of kidney outcomes among the 268/330 (81%) of patients in ADVOCATE with kidney disease at baseline
Slide 52: Change in UACR from baseline in patients with kidney involvement
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Change in UACR from baseline in patients with kidney involvement and baseline UACR > 300 mg/g. Kidney Int Rep 2025
Slide 53: Kidney outcome in ADVOCATE among patients with eGFR ≤20
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH 2025 Analysis of kidney outcome in ADVOCATE among patients with eGFR ≤20 ml/min per 1.73 m2 N=50 patients
Slide 54: Change in kidney function among patients with baseline eGFR ≤20
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Change in kidney function among patients in the ADVOCATE trial with baseline eGFR ≤20 ml/min per 1.73 m2. *P < 0.05 **P < 0.01 Kidney Int Rep 2023
Slide 55: Treatment of AAV: Unmet Needs
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Treatment of AAV: Unmet Needs Less toxic regimens - Glucocorticoid-sparing - CYC-sparing/avoiding - Non-sterilizing & non-teratogenic drugs - Reduction in infections More rapid induction of remission Prevention of r
Slide 56: Benefits of More Rapid Induction of Remission of AAV
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Benefits of More Rapid Induction of Remission of AAV Prevent progression to organ- or life-threatening status Preserve kidney function predictor of long-term outcome Prevent damage to other organs; e.g. nerves,
Slide 57: Treatment of AAV: Unmet Needs
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Treatment of AAV: Unmet Needs Less toxic regimens - Glucocorticoid-sparing - CYC-sparing/avoiding - Non-sterilizing & non-teratogenic drugs - Reduction in infections More rapid induction of remission Prevention of r
Slide 58: The Potential of Enhanced Complement Inhibition for the Treatment of AAV
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH The Potential of Enhanced Complement Inhibition for the Treatment of AAV Stronger/better complement inhibition could result Overall better outcomes Faster remission Faster and greater recovery of kidney functio
Slide 59: Summary
Standard of Care and Unmet Needs in AAV November 3, 2026 Peter A. Merkel, MD, MPH Summary Treatment of patients with AAV has improved markedly over the past 25 years However, the rates of remission, relapse-free remission, and prevention of organ damage, especially kidney function, remain unacce
Slide 60: Izicopan
• InflaRx N.V. Izicopan Next-generation oral C5aR inhibitor
Slide 61: Potential for better efficacy: fast onset with deep C5aR blockade
Potential for better efficacy: fast onset with deep C5aR blockade Izicopan Avacopan FAST ONSET OF ACTION Week 1 ~10× higher exposure AUC (h·ng/mL) after a single 30 mg dose, Phase 1** 557 5,197 Izicopan exceeds avacopan’s steady state exposure within first week* ≥90% C5a blockade in 24 h 94% Ex vivo
Slide 62: Potential for better safety: lower liver and drug-drug interaction risk
Potential for better safety: lower liver and drug-drug interaction risk No time-dependent CYP3A4/5 inhibition* REACTIVE METABOLITES* Izicopan: no TDI in Ki/kinact assay; IC50 Avacopan: TDI of CYP3A4/5; midazolam >100-fold lower >100 µM AUC up 1.8-fold reactive-metabolite signal than avacopan in the
Slide 63: Better convenience: simpler dosing and fewer drug-drug interactions
Better convenience: potential for simpler dosing and fewer drug-drug interactions Once-daily [QD] dosing potential PILL BURDEN Izicopan: 30 mg QD reached ≥90% C5a Avacopan: twice daily, 3 capsules per pill count blockade by day 6, phase 1*, supported by PK modeling of phase 2 data dose at equivalent
Slide 64: Izicopan differentiation driven by optimized molecular structure
Izicopan differentiation driven by optimized molecular structure Modelling indicates that the additional Maestro 14.4.136 Docking Maestro 14.4.136 Docking trifluoromethyl group in izicopan Avacopan – CYP3A/4 Izicopan – CYP3A/4 introduces steric interactions (clashes) within the CYP3A4/5 binding pock
Slide 65: Izicopan: AAV market considerations
• InflaRx N.V. Izicopan AAV market considerations
Slide 66: Market research: Physicians back izicopan as next-generation C5aR inhibitor
Market research: Physicians back izicopan as the next-generation C5aR inhibitor C5a/C5aR blockade remains a key target – physicians see izicopan’s profile as a potentially safer, more convenient successor with added potential kidney upside 10/12 8/10 65-70% 7/12 retain confidence in likelihood to pr
Slide 67: Izicopan in AAV: ~$1.5-2B global peak net sales potential
Izicopan in AAV: ~$1.5-2B global peak net sales potential1 Avacopan proven demand with $645M sales in 2025 and $1B+ peak sales potential2 before exiting key markets Sensitivity analysis: Peak izicopan sales by scenario, Base-case izicopan global peak net sales $M (ONLY in US + EU4/UK, excl. ROW) $1.
Slide 68: AAV clinical development program
• InflaRx N.V. AAV clinical development program
Slide 69: Izicopan in AAV – capturing the opportunity
Izicopan in AAV – capturing the opportunity Development Goals (A) Demonstrate superiority with focus on renal endpoints in randomized placebo-controlled Phase 2 – Randomized, placebo-controlled Phase 2 trial optimized to increase signal delta to placebo by allowing severely ill AAV patients with ren
Slide 70: Randomized, placebo-controlled Ph2 trial design
Randomized, placebo-controlled Ph2 trial design Screening Induction Wk 24 Maintenance Wk 48 Wk 52 Arm 1: Placebo BID + RTX Placebo BID + RTX Safety FU Arm 2: IZI 30 mg BID + RTX Safety IZI 30 mg BID + RTX FU Arm 3: IZI 60 mg BID + RTX Safety IZI 60 mg BID + RTX FU • Testing 2 doses on top of SOC (RT
Slide 71: Open-label AAV Ph2 trial design planning
Open-label AAV Ph2 trial design planning Induction Wk 16 Wk 24 Maintenance Wk 48 Safety Stage 1 IZI 60 mg BID + rapid GC taper + SOC IZI 60 mg BID + SOC maintenance FU Safety Assessment Wk 16 Wk 24 Wk 48 Safety Stage 2 IZI 60 mg BID + SOC (no GC) IZI 60 mgIZIBID 60 +mg BIDmaintenance SOC + SOC maint
Slide 72: Development opportunities in additional renal disorders
• InflaRx N.V. Development opportunities in additional renal disorders
Slide 73: Planned izicopan pilot study in IgAN / RPGN in IgAN
Planned izicopan pilot study in IgAN / RPGN in IgAN – signal searching Screening Wk 12 Wk 24 Wk 28 IZI 60 mg BID on top of SOC Safety FU • Open label study to assess safety and explore efficacy in patients with IgAN and IgAN RPGN (rapidly progressive glomerulonephritis) • Cohort may be expanded base
Slide 74: IIT in patients with atypical hemolytic uremic syndrome (aHUS)
IIT in patients with atypical hemolytic uremic syndrome (aHUS) Screening Wk 1 Wk 12 Wk 24 Wk 48 Safety IZI 60mg BID FU Initial response assessment Eculizumab rescue at any time past week 1 - if rescue occurs, izicopan will be stopped • Key efficacy focus is TMA response (platelet count normalization
Slide 75: Today's takeaways
Today’s takeaways § Izicopan has potential to expand the AAV market, with multiple differentiating features that could drive a $1.5B – $2B peak sales potential § Izicopan AAV development program is primed for generating differentiated efficacy and safety data - placebo-controlled study in patients w
Slide 76: InflaRx N.V. (IFRX)
• InflaRx N.V. InflaRx N.V. (IFRX) Winzerlaer Str. 2 07745 Jena, Germany Email: [email protected] Tel: +49-3641-508180 Fax: +49-3641-508181 www.inflarx.com